<DOC>
	<DOCNO>NCT00472758</DOCNO>
	<brief_summary>-To evaluate safety tolerability multiple dos drug adult patient .</brief_summary>
	<brief_title>A Multicenter Study Evaluate Safety Tolerability Single-Dose MEDI-545</brief_title>
	<detailed_description>-The primary objective study evaluate safety tolerability escalate single IV dose MEDI-545 adult patient chronic plaque psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female adult , age 18 70 year age time screen ; Written inform consent obtain patient prior receipt study medication begin study procedure ; Documented clinical history chronic plaque psoriasis ; ≥ 3 % body surface area ( BSA ) involvement affect skin face scalp ; Have least two target plaque suitable serial photographic assessment , one size location allow serial biopsy ; No significant change regular psoriasis treatment least 28 day screen time study drug administration ; Sexually active woman , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , abstinence , use condom spermicide sexual partner sterile sexual partner ) 21 day prior study drug administration , must agree continue use precaution Study Day 126 . Cessation birth control point discuss responsible physician . Sexually active men , unless surgically sterile , must likewise use effective method birth control ( condom spermicide ) must agree continue use precaution Study Day 126 ; Willing forego form experimental treatment study procedure study ; Ability complete study period , include followup period Study Day 126 . Receipt MEDI545 previous clinical study ; History allergy reaction component MEDI545 formulation ; Pustular , guttate , erythrodermic psoriasis predominant disease type ; Current use potent topical corticosteroid , tacrolimus , calcipotriol 28 day prior screen study drug administration ; Current use phototherapy include tan bed , Goeckerman modify Goeckerman regimen , systemic corticosteroid , cyclosporin A , azathioprine , mycophenolate mofetil , methotrexate , systemic treatment psoriasis within 28 day prior screen study drug administration ; Current use biologic agent alefacept tumor necrosis factorα inhibitor within 90 day prior screen study drug administration ; Any disease illness , chronic plaque psoriasis , may require use systemic corticosteroid study period ; Acute illnesses evidence significant active infection , fever ≥ 38.0°C ( ≥ 100.5°F ) screening study drug administration ; Receipt investigational drug therapy attenuate live vaccine therapy ( vaccination influenza ) within 30 day 5 halflife period ( whichever longer ) prior study drug administration end study ; Pregnancy ( sexually active woman , unless surgically sterile least 1 year postmenopausal , must negative serum pregnancy test screen negative urine pregnancy test prior study drug administration Study Day 0 ) ; Breastfeeding lactate woman ; Evidence infection hepatitis B C virus , human immunodeficiency virus ( HIV ) 1 2 , active infection hepatitis A , determined result test screening ; A history severe infection cytomegalovirus viruses herpes family include EpsteinBarr virus require hospitalization , disseminate herpes , herpes encephalitis , ophthalmic herpes ; Herpes zoster within 3 month prior screen ; Current suppressive antiviral therapy herpes viral infection ; A history cancer except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy ≥ 1 year prior randomization ; Elective surgery plan study period end study ; Clinically significant abnormality , determine investigator , 12lead electrocardiogram ( ECG ) chest radiograph screening ; A history coagulation disorder ; History primary immunodeficiency ; History stroke , cerebrovascular disease require current medication/treatment ; In opinion investigator , clinically significant active cardiac disease , include : unstable angina ; myocardial infarction within 6 month ; congestive heart failure ; arrhythmia require active therapy ; Ongoing , clinically significant ( opinion investigator ) chronic infectious disease ; History active tuberculosis positive tuberculosis ( TB ) test ( define reaction ≥ 10 mm diameter ) without complete course appropriate medical treatment ; At time screen , follow : clinically significant abnormality hemoglobin , total white blood cell count , platelet count ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 1.5 time upper limit normal ( ULN ) , serum creatinine , prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; ULN ; Any abnormal laboratory value screen panel , opinion investigator , clinically significant . Abnormal result screen laboratory test may repeat discretion site investigator ( ) qualify designee , prior Study Day 0 , determine eligibility ; Evidence systemic disease skin disease ( chronic plaque psoriasis ) , find upon physical examination history disease , opinion investigator , designate health care provider , medical monitor , may compromise safety patient study confound analysis study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>